New combo therapy tested for lung cancer patients with HIV
NCT ID NCT04499053
Summary
This study is testing whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy is safe and effective for treating advanced non-small cell lung cancer in people who also have HIV. It will enroll 18 adults with stage IV lung cancer who are on stable HIV medication. The main goals are to see if the treatment causes serious side effects and if it shrinks the tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
RECRUITINGBaltimore, Maryland, 21237, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Marlene and Stewart Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medstar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.